Infectious Diseases

The Clinician's Companion:
Changing the Treatment Paradigm to
Improve Fungal Infection Outcomes

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CPE activities may not contain the most up-to-date information available.

Click here to view our current activities in Infectious Diseases.

Breaking the Mould: What's New in Antifungal Therapy?

Earn up to 13 CME/CPE credits in this activity, which consists of five case-based newsletters, five audio CDs featuring interviews with the expert faculty on related issues, and a comprehensive monograph on fungal infections.

Download these outstanding educational activities or order your complimentary boxed set of all components today!

Sincerely,

CO-CHAIRS
Thomas F. Patterson, MD Professor of Medicine Department of Medicine The University of Texas Health Science Center at San Antonio San Antonio, Texas	John R. Wingard, MD Professor of Medicine Department of Medicine University of Florida Gainesville, Florida
FACULTY
Elias J. Anaissie, MD Professor of Medicine Director, Division of Supportive Care Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences Little Rock, Arkansas	Helen L. Leather, BPharm Clinical Pharmacy Specialist BMT/Leukemia Department of Pharmacy Shands at the University of Florida Gainesville, Florida
Gregory M. Anstead, MD, PhD Assistant Professor Department of Medicine Division of Infectious Diseases The University of Texas Health Science Center at San Antonio San Antonio, Texas	James S. Lewis, PharmD Infectious Diseases Pharmacy Specialist University Health System Department of Pharmacy and UTHSC-SA Department of Pharmacology San Antonio, Texas
Helen W. Boucher, MD Assistant Professor of Medicine Division of Infectious Diseases Tufts-New England Medical Center Boston, Massachusetts	Kieren A. Marr, MD Assistant Member Program in Infectious Diseases Fred Hutchinson Cancer Research Center Seattle, Washington
Neil Clancy, MD Assistant Professor Department of Medicine University of Florida College of Medicine Gainesville, Florida	Minh-Hong Nguyen, MD Associate Professor Department of Medicine University of Florida Gainesville, Florida
Carol A. Kauffman, MD Professor of Internal Medicine Division of Infectious Diseases Veterans Affairs Ann Arbor Healthcare System University of Michigan Medical School Ann Arbor, Michigan	Nina Singh, MD Associate Professor of Medicine Infectious Diseases Section University of Pittsburgh Pittsburgh, Pennsylvania
David A. Kaufman, MD Associate Professor Department of Pediatrics University of Virginia School of Medicine Charlottesville, Virginia	Jack D. Sobel, MD Professor of Medicine Chief, Division of Infectious Diseases Detroit Medical Center Wayne State University, School of Medicine Detroit, Michigan

top

TARGET AUDIENCE

This activity is designed for infectious disease specialists, hematologists, oncologists, hospital pharmacists, and transplant surgeons who treat patients who are immunocompromised due to their primary clinical status and/or therapeutic regimen and are therefore susceptible to opportunistic fungal infections.

LEARNING OBJECTIVES

Identify fungal pathogens commonly diagnosed in the immunocompromised patient to ensure early diagnosis and treatment.
Analyze potential resistance patterns among fungal pathogens.
Assess and incorporate the current guidelines in the treatment of fungal infections.
Formulate optimal treatment strategies utilizing knowledge of susceptibility testing, efficacy, and safety of available and emerging therapies.
Integrate mycosis prophylaxis strategies to improve at-risk patient outcomes.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 13 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Each newsletter/audio CD is worth up to 2 credits and the monograph is worth up to 3 credits.

The monograph and each newsletter/audio CD in this series are planned and produced as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CPE Information: Pharmacists

Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. Each newsletter/audio CD is worth up to 2 contact hours (.2 CEUs), and the monograph is worth up to 3 contact hours (.3 CEUs). See individual newsletter/audio CD and monograph for activity provider numbers.

CME/CPE Instructions

To obtain CME/CPE credit for this activity:

Read and listen to this activity carefully.
Complete/submit each posttest and evaluation.
Instantly access and print out your certificates.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Elias J. Anaissie, MD, has received grant/research support from Astellas Pharma US, Inc, CuraGen Corporation, and Pfizer Inc; is a consultant for Astellas Pharma US, Inc, Gilead Sciences, Inc, Merck & Co, Inc, and Pfizer Inc; and is on the speakers bureau of Astellas Pharma US, Inc, Merck & Co, Inc, and Pfizer Inc.

Gregory M. Anstead, MD, PhD, has received grant/research support from Schering-Plough Corporation; and has received honoraria from, is on the speakers bureau of, and is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Gilead Sciences, Inc, Pfizer Inc, and Schering-Plough Corporation.

Helen W. Boucher, MD, is a consultant for Aspreva Pharmaceuticals, Cubist Pharmaceuticals, Pfizer Inc, and Schering-Plough Corporation; is on the speakers bureau of Pfizer Inc; has received consulting fees from Cubist Pharmaceuticals, Pfizer Inc, and Schering-Plough Corporation; has received honoraria from Cubist Pharmaceuticals and Pfizer Inc; and has ownership interest in Cubist Pharmaceuticals.

Neil Clancy, MD, has received grant/research support from Pfizer Inc.

Carol A. Kauffman, MD, has received grant/research support from Astellas Pharma US, Inc, Enzon Pharmaceuticals, Merck & Co, Inc, and Schering-Plough Corporation; and is on the speakers bureau of Astellas Pharma US, Inc, Merck & Co, Inc, and Schering-Plough Corporation.

David A. Kaufman, MD, is a consultant for Astellas Pharma US, Inc.

Helen L. Leather, BPharm, is a consultant for Enzon Pharmaceuticals, Pfizer Inc, and Schering-Plough Corporation; is on the speakers bureau of Amgen Inc, Astellas Pharma US, Inc, Enzon Pharmaceuticals, Merck & Co, Inc, and Pfizer Inc; and has received consulting fees from Pfizer Inc and Schering-Plough Corporation.

James S. Lewis, PharmD, is a consultant for Pfizer Inc and Schering-Plough Corporation; and is on the speakers bureau of, and has received consulting fees from, Astellas Pharma US, Inc and Pfizer Inc.

Kieren A. Marr, MD, has received grant/research support from Astellas Pharma US, Inc, Merck & Co, Inc, and Pfizer Inc; is a consultant for Astellas Pharma US, Inc, Enzon Pharmaceuticals, Merck & Co, Inc, Pfizer Inc, and Schering-Plough Corporation.

Minh-Hong Nguyen, MD, has indicated no significant relationships with industry.

Thomas F. Patterson, MD, has received grant/research support from Astellas Pharma US, Inc, Enzon Pharmaceuticals, Merck & Co, Inc, Pfizer Inc, and Schering-Plough Corporation; is a consultant for, and has received consulting fees from, Affinium Pharmaceuticals, Astellas Pharma US, Inc, Basilea Pharmaceuticals, Diversa, Eisai, Inc, Human Genome Sciences, Inc/CoGenesys, J. Uriach & Cia S.A., MediciNova, Merck & Co, Inc, Microbia, Nektar Therapeutics, Pfizer Inc, Rib-X Pharmaceuticals, and Schering-Plough Corporation; and is on the speakers bureau of Astellas Pharma US, Inc, Merck & Co, Inc, Pfizer Inc, and Schering-Plough Corporation.

Nina Singh, MD, has received grant/research support and consulting fees from Schering-Plough Corporation.

Jack D. Sobel, MD, has received grant/research support from Astellas Pharma US, Inc, Merck & Co, Inc, NIH RCSI, Mtec, Pfizer Inc, and Presutti Laboratories; and is a consultant for Merck & Co, Inc, Pfizer Inc, Presutti Laboratories, and 3M Pharmaceuticals.

John R. Wingard, MD, has received grant/research support from Merck & Co, Inc and Pfizer Inc; is a consultant for, and has received honoraria from, Enzon Pharmaceuticals, Merck & Co, Inc, Pfizer Inc, and Schering-Plough Corporation; is on the speakers bureau of Enzon Pharmaceuticals, Merck & Co, Inc, and Pfizer Inc; has received consulting fees from Merck & Co, Inc and Pfizer Inc; and is an investigator for Ortho Biotech Products, LP and Schering-Plough Corporation.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

There will be discussion of unlabeled/unapproved uses of drugs or devices in these activities. Specific product disclosure will be forthcoming in each activity.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CPE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CPE activity is supported by an educational grant from
Schering-Plough Corporation.

top

1744